Funders › FL › Scott R Mackenzie Foundation Inc › 2021
Grants paid by Scott R Mackenzie Foundation Inc, tax year 2021
EIN 46-3383293 · Jacksonville, FL · Form 990-PF, Part XV · NTEE T22
In tax year 2021, Scott R Mackenzie Foundation Inc (EIN 46-3383293) reported 6 grants paid totaling $1,008,269. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2021
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2021 | Mount Desert Island Biological Laboratory Bar Harbor, ME | B | $400,000 | paid | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO PREVENT ORGAN COMPLICATIONS IN DIABETIC PATIENTS. HIGH GLUCOSE LEVELS LEAD TO THE PATHALOGICAL CHANGES IN THE VASCULATURE OF DIFFERENT ORGANS SUCH AS THE HEART, KIDNEY, EYE AND PERIPHERAL CIRCULATION. THE FOCUS IS THE MICROCIRCULATION OF THE KIDNEY. THE ENDOTHELIAL CELL SURFACE IS COVERED WITH A LAYER OF GLYCOCALYX. THE GLYCOCALYX IS VERY IMPORTANT FOR THE HEALTH OF THE VASCULAR WALL AND REGULATES CENTRAL MECHANISMS SUCH AS METABOLISM, INFLAMMATION, BLOOD PRESSURE, ETC. WE WILL TEST THE HYPOTHESIS THAT RECOMBINANT HPA2 AMELIORATES DIABETIC NEPHROPATHY BY MAINTAINING A FUNCTIONAL HEPARAN SULFATE GLYCOCALYX ON ENDOTHELIAL CELLS AND MONOCYTES. | 202310469349101406 |
| 2021 | University of Arizona Tucson, AZ | U | $175,006 | paid | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO IMPROVE THE DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. TO DEVELOP PATIENT-SPECIFIC TARGETED NEXT-GENERATION GENE SEQUENCING FOR PREDICTING AND DIAGNOSING ATRIAL FIBRILLATION AND ESTABLISH A PATIENT-SPECIFIC STEM CELL PLATFORM FOR DEVELOPING PRECISION MEDICINE BASED TREATMENTS. | 202310469349101406 |
| 2021 | University of Florida Foundation Gainesville, FL | B | $150,000 | paid | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO BROADEN THE DISCOVERY OF NEW PANCREATIC CANCER BIOMARKERS THROUGH GENOMIC SEQUENCING. BY SEQUENCING TUMOR AND NORMAL SAMPLES FROM OUR PATIENTS, WE CAN DETERMINE NOVEL CANCER DRIVERS INCLUDING MUTATIONS, FUSIONS, AND GENE EXPRESSION ALTERATIONS THAT DRIVE THESE CANCERS. NEW BIOMARKERS WILL INTRODUCE NEW POTENTIAL TARGETS FOR TREATMENT AND EARLY DETECTIONS. | 202310469349101406 |
| 2021 | Israel Cancer Research Fund New York, NY | B | $148,500 | paid | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO ASK HOW DNA REPAIR IS ORCHESTRATED DESPITE THE PACKAGING OF DNA INTO CHROMATIN. SWI/SNF PROTEINS ESTABLISH AND MAINTAIN CHROMATIN STRUCTURE. SUBUNITS OF SWI/SNF PROTEINS ARE MUTATED IN 20% OF CANCERS, IMPLICATING THEM IN CARCINOGENESIS, AND MAKING THEM ATTRACTIVE CANDIDATES FOR CANCER-SPECIFIC AND SELECTIVE THERAPIES. DR. ADAR EXPECTS TO ESTABLISH THAT SWI/SNF REMODELERS FACILITATE SPECIFIC STEPS IN NUCLEOTIDE EXCISION REPAIR (NER) IN CHROMATIN TEMPLATES, AND THAT CANCER ASSOCIATED MUTANTS ARE DEFICIENT IN THIS FUNCTION. THIS NEW UNDERSTANDING OF SWI/SNF FUNCTIONS CAN THEN BE LEVERAGED TO DESIGN NEW CANCER DIAGNOSTICS AND CHEMOTHERAPEUTICS. | 202310469349101406 |
| 2021 | University of Florida Foundation Gainesville, FL | B | $125,000 | paid | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THE GIFT TO ASSESS POTENTIAL DRUG INTERACTIONS BETWEEN CANGRELOR AND NOVEL P2Y12 INHIBITORS AND EVALUATE THE IMPACT OF RECEPTOR EXPRESSION ON THEIR FINDINGS. | 202310469349101406 |
| 2021 | Mayo Clinic Jacksonville, FL | U | $9,763 | paid | THE BENEFACTOR DESIRES THAT GRANTEE SHALL USE THIS GIFT TO SUPPORT THE TAPESTRY STUDY. | 202310469349101406 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.